Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

NCT06847321 is registered in ClinicalTrials.gov with Lighthouse Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06847321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06847321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lead sponsor
Lighthouse Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
February 17, 2025
Completion date
March 15, 2029
Enrollment
300 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, alzheimer disease due to p. gingivalis